Therefore, because previous studies showed patients with somatic mutations in HRR genes, including BRCA1 and BRCA2, benefited from treatment with PARP inhibitors [5–7], our analysis suggests that tumour testing could identify nearly 50% more patients with BRCA mutations that may benefit from a PARP inhibitor than germline testing alone. This evidence concerns the gene BRCA2 and neoplasm.